Tin tức & Cập nhật

Chỉ hiển thị Multimedia
Dupilumab trumps MTX, cyclosporine in paediatric AD

Dupilumab trumps MTX, cyclosporine in paediatric AD

03 Feb 2025 bởiStephen Padilla

The use of dupilumab in children with moderate-to-severe atopic dermatitis (AD) results in greater improvements in AD severity, better adherence, and fewer treatment-emergent adverse events (TEAEs) than methotrexate (MTX) or cyclosporine, as shown by 2-year interim results from the PEDISTAD study.

Dupilumab trumps MTX, cyclosporine in paediatric AD

03 Feb 2025
COVID-linked MIS-C outcomes reassuring at 6 months

COVID-linked MIS-C outcomes reassuring at 6 months

31 Jan 2025
Dupilumab-associated ocular surface disease less common in children, teens with AD

Dupilumab-associated ocular surface disease less common in children, teens with AD

18 Jan 2025